AVITA Medical, Inc. (RCEL) Receivables (2018 - 2026)

AVITA Medical (RCEL) has reported Receivables for 9 consecutive years, with $9.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables fell 12.72% year-over-year to $9.9 million; the trailing twelve-month figure through Jun 2026 stood at $9.9 million (down 12.72% YoY), and the FY2025 full-year result was $9.1 million, down 23.25% from the prior year.
• Receivables climbed to $9.9 million in Q2 2026 per RCEL's latest filing, from $9.1 million in the prior quarter.
• Across five years, Receivables topped out at $12.0 million in Q1 2025 and bottomed at $3.6 million in Q4 2022.
• Historically, Receivables has averaged $7.7 million across 5 years, with a median of $7.5 million in 2023.
• The widest YoY moves for Receivables: up 2120.93% in 2022, down 39.37% in 2022.
• Over 5 years, Receivables stood at $3.6 million in 2022, then soared by 106.93% to $7.5 million in 2023, then soared by 56.75% to $11.7 million in 2024, then declined by 22.52% to $9.1 million in 2025, then increased by 8.79% to $9.9 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $9.9 million, $9.1 million, and $9.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.